SCHEMBL5535564

SCHEMBL5535564

CCCCCN1CC[N]CC1=O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
GBA1 P04062 1/20 0.41
MGLL Q99685 4/20 0.38
FAAH O00519 3/20 0.38
ALOX5 P09917 2/20 0.36
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PLA2G2A P14555 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535499 0.98 GBA1 (0.43) ALDH1A1GAAMAPTTHRBGBA1
SCHEMBL5542498 0.95 ALDH1A1 (0.38) ALDH1A1GAAMAPTTHRBGBA1
SCHEMBL5548447 0.87 POLB (0.34) ALDH1A1GAAMAPTTHRBNPC1
SCHEMBL1316047 0.79
SCHEMBL667538 0.76 TOP2A (0.34)
SCHEMBL5106801 0.75 ALDH1A1 (0.34) ALDH1A1KDM4ENPC1HPGDRAB9A
SCHEMBL4017035 0.75 MGLL (0.47) ALDH1A1GAAMAPTTHRBGBA1
SCHEMBL9632622 0.74 GBA1 (0.42) ALDH1A1GAAMAPTTHRBGBA1
SCHEMBL11264220 0.73 ALDH1A1 (0.51) ALDH1A1GAAMAPTTHRBGBA1
SCHEMBL11252637 0.73 ALDH1A1 (0.51) ALDH1A1GAAMAPTTHRBGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885GAA 4165/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.